- In recent weeks, Agilent Technologies secured FDA approval for an expanded PD-L1 IHC 22C3 pharmDx cancer companion diagnostic indication and introduced the BioTek Cytation 9 cell imaging multimode reader, while the U.S. Supreme Court let stand rulings invalidating two of its CRISPR-related patents.
- This combination of a broader clinical diagnostic role alongside a new high-content lab instrument launch, set against a legal setback in gene-editing IP, reshapes how investors may view Agilent’s mix of innovation, product portfolio depth, and competitive positioning.
- Next, we’ll explore how the new esophageal cancer companion diagnostic approval influences Agilent’s longer-term investment narrative and risk profile.
The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
Agilent Technologies Investment Narrative Recap
To own Agilent, you really need to believe in its role as a core tools and diagnostics supplier to pharma, advanced materials and testing labs, supported by recurring consumables and services. The latest FDA companion diagnostic approval and Cytation 9 launch both support that story, while the CRISPR patent loss looks contained for now and does not obviously displace the current key near term catalyst or the main margin and funding risks.
Among the recent announcements, the FDA approval expanding PD L1 IHC 22C3 pharmDx to esophageal and gastroesophageal junction cancer is most relevant, because it deepens Agilent’s footprint in regulated clinical diagnostics tied to KEYTRUDA. That kind of test menu expansion directly connects to the core catalysts around rising healthcare testing demand and higher margin recurring revenue from diagnostics kits and associated services.
Yet, against this constructive backdrop, investors still need to weigh the risk that rising tariffs and supply chain complexity could...
Read the full narrative on Agilent Technologies (it's free!)
Agilent Technologies' narrative projects $8.6 billion revenue and $2.0 billion earnings by 2029.
Uncover how Agilent Technologies' forecasts yield a $163.19 fair value, a 43% upside to its current price.
Exploring Other Perspectives
Five members of the Simply Wall St Community value Agilent between US$124.89 and US$163.19 per share, reflecting varied expectations. You should weigh this spread against risks like tariff driven cost pressures that could affect margins and future flexibility.
Explore 5 other fair value estimates on Agilent Technologies - why the stock might be worth just $124.89!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Agilent Technologies research is our analysis highlighting 4 key rewards that could impact your investment decision.
- Our free Agilent Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Agilent Technologies' overall financial health at a glance.
Want Some Alternatives?
Opportunities like this don't last. These are today's most promising picks. Check them out now:
- Uncover the next big thing with 33 elite penny stocks that balance risk and reward.
- We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- Outshine the giants: these 20 early-stage AI stocks could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com